Colon Cancer News and Research RSS Feed - Colon Cancer News and Research

Every year, about one million new cases of colon cancer are diagnosed worldwide. About 150,000 new cases are detected each year in the United States. Over a lifetime, about 1 in 19 people develop colon cancer and nearly 50,000 people are expected to die from it in the U.S. this year. According to the American Cancer Society, colon cancer is the third leading cause of cancer-related death in the U.S., accounting for about 10 percent of all cancer deaths.
Small antioxidant molecules suppress colon cancer associated with colitis

Small antioxidant molecules suppress colon cancer associated with colitis

Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis. [More]
SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it. [More]
Death rates remain higher for African-Americans with colon cancer

Death rates remain higher for African-Americans with colon cancer

African-Americans with colon cancer are half as likely as Caucasian patients to have a type of colon cancer that is linked to better outcomes. The finding may provide insight into why African-Americans are more likely to die of colon cancer than Caucasians with the same stage of disease. [More]
Colon has safety mechanism to restrict formation and growth of adenomas

Colon has safety mechanism to restrict formation and growth of adenomas

Colon cancer development starts with the formation of benign tumours called adenomas. It is estimated that between 30% and 50% of people over 50 will develop one of these tumours. [More]
Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

This report estimated the effect of the Affordable Care Act (ACA) on 14 large and diverse cities: Los Angeles, Chicago, Houston, Philadelphia, Phoenix, Indianapolis, Columbus, Charlotte, Detroit, Memphis, Seattle, Denver, Atlanta, and Miami. [More]
Six essential screening tests all men should receive during lifetime

Six essential screening tests all men should receive during lifetime

When it's comes men and health, the numbers don't stack up. Compared to women, men are 24 percent less likely than women to visit the doctor, according to the U.S. Department of Health & Human Services. Yet, men are 28 percent more likely than women to be hospitalized for congestive heart failure and 32 percent more likely to receive care for complication of diabetes. [More]
EU-funded project aims to identify potential new targets for cancer therapy

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner. [More]
Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology. [More]
Gene variants that lead to longer telomeres boost brain cancer risk

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas. [More]
PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. [More]
Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Myriad Genetics, Inc. today presented several clinical studies on the Myriad myRisk- Hereditary Cancer test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Illinois. [More]
Scientists discover link between circadian clock disturbances and inflammatory diseases

Scientists discover link between circadian clock disturbances and inflammatory diseases

A disruption of circadian rhythms, when combined with a high-fat, high-sugar diet, may contribute to inflammatory bowel disease and other harmful conditions, according to a recent study conducted by researchers at Rush University Medical Center. [More]
Researchers show how bacteria responsible for strep throat can be used to fight colon cancer

Researchers show how bacteria responsible for strep throat can be used to fight colon cancer

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer. [More]
Loyola’s Gastrointestinal Cancer Risk Assessment Program provides state-of-the-art care to cancer patients

Loyola’s Gastrointestinal Cancer Risk Assessment Program provides state-of-the-art care to cancer patients

Patients at increased risk for gastrointestinal cancer now have access to a new multidisciplinary program at Loyola University Health System. [More]
Interactive multimedia computer program fails to increase colorectal cancer screening rates

Interactive multimedia computer program fails to increase colorectal cancer screening rates

Colorectal cancer screening saves lives, but too few people get tested. In an effort to increase these numbers,researchers from UC Davis and elsewhere investigated whether an individualized interactive multimedia computer program (IMCP) would spur patients to get screened. [More]
Study provides potential target for cutting off growth of cancer stem cells

Study provides potential target for cutting off growth of cancer stem cells

A subset of immune cells directly target colon cancers, rather than the immune system, giving the cells the aggressive properties of cancer stem cells. [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Research roundup: Compounding pharmacies; marketplace details; changes in insurance coverage

Outraged over a 2012 fungal meningitis outbreak traced back to Framingham, Massachusetts-based drug compounder New England Compounding Center (NECC) that left sixty-four people dead and more than 700 sickened, Congress passed the Compounding Quality Act . [More]
New health system scorecard reveals wide health gaps among states

New health system scorecard reveals wide health gaps among states

States made little progress in improving health care access, quality, and outcomes and lowering costs in the five years preceding implementation of the major coverage provisions of the Affordable Care Act (2007-2012), according to the Commonwealth Fund's third state health system scorecard. The majority of states declined or failed to improve on two-thirds of the 34 scorecard indicators that could be tracked over time. [More]
Researchers develop new strategy to personalised medicine in advanced cancer patients

Researchers develop new strategy to personalised medicine in advanced cancer patients

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours. [More]